Published in

Oxford University Press, British Journal of Surgery, 12(102), p. 1459-1472, 2015

DOI: 10.1002/bjs.9892

Links

Tools

Export citation

Search in Google Scholar

Meta-analysis of radical resection rates and margin assessment in pancreatic cancer

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractBackgroundR0 resection rates (complete tumour removal with negative resection margins) in pancreatic cancer are 70–80 per cent when a 0-mm margin is used, declining to 15–24 per cent with a 1-mm margin. This review evaluated the R0 resection rates according to different margin definitions and techniques.MethodsThree databases (MEDLINE from 1946, PubMed from 1946 and Embase from 1949) were searched to mid-October 2014. The search terms included ‘pancreatectomy OR pancreaticoduodenectomy’ and ‘margin’. A meta-analysis was performed with studies in three groups: group 1, axial slicing technique (minimum 1-mm margin); group 2, other slicing techniques (minimum 1-mm margin); and group 3, studies with minimum 0-mm margin.ResultsThe R0 rates were 29 (95 per cent c.i. 26 to 32) per cent in group 1 (8 studies; 882 patients) and 49 (47 to 52) per cent in group 2 (6 studies; 1568 patients). The combined R0 rate (groups 1 and 2) was 41 (40 to 43) per cent. The R0 rate in group 3 (7 studies; 1926 patients) with a 0-mm margin was 72 (70 to 74) per cent The survival hazard ratios (R1 resection/R0 resection) revealed a reduction in the risk of death of at least 22 per cent in group 1, 12 per cent in group 2 and 23 per cent in group 3 with an R0 compared with an R1 resection. Local recurrence occurred more frequently with an R1 resection in most studies.ConclusionMargin clearance definitions affect R0 resection rates in pancreatic cancer surgery. This review collates individual studies providing an estimate of achievable R0 rates, creating a benchmark for future trials.